Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are widely heterogeneous malignant abnormalities.1 Their natural history is poorly described, with little understanding of recurrence patterns. Surveillance for resected GEP-NETs may include clinical review, laboratory tests, and numerous medical and nuclear imaging modalities. These modalities can increase patient anxiety, may be associated with potential harm (eg, exposure to ionizing radiation), and have not been shown to improve outcomes. Current guidelines vary widely in recommendations, reflecting the lack of data.2,3 Information on the natural history and recurrence of the disease may improve patient-centered follow-up of this population. We hypothesized that GEP-NETs may recur over a longer time course compared with other gastrointestinal malignant abnormalities.
Singh S, Chan DL, Moody L, et al. Recurrence in Resected Gastroenteropancreatic Neuroendocrine Tumors. JAMA Oncol. 2018;4(4):583–585. doi:10.1001/jamaoncol.2018.0024
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: